AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational ...

Joanna Robles, MD, first began having unusual symptoms in the summer of 2020. She had bouts of nausea and vomiting that she couldn’t explain. Eventually doctors diagnosed her with neuromyelitis optica ...

In the autoimmune disorder neuromyelitis optica (NMO), the immune system attacks the optic nerves and spinal cord. This can cause symptoms such as loss of vision and changes in sensation. Early and ...

The early diagnosis and treatment of neuromyelitis optica (NMO) generally improve the outlook for people with this condition. Corticosteroids and immunotherapy are the main treatment options. NMO, ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A woman who contracted a rare disease that left her paralyzed from the ...

Autoimmune diseases are the molecular equivalent of "friendly fire": The body attacks itself instead of harmful invaders. Now, researchers from Japan have found that interrupting the complex interplay ...

A monoclonal antibody (mAb) against a glycoprotein called repulsive guidance molecule-a (RGMa) may provide an efficient therapeutic strategy for treating neuromyelitis optica (NMO), scientists at ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of patients ...

A systematic review found the highest incidence and prevalence of NMO/NMOSD among Caribbean-African populations. Middle-aged adults—those between 40 and 59 years old—had the highest incidence rates of ...

DENVER (CBS4)- Monday is Rare Disease Awareness Day and CBS4 is highlighting a Denver teenager who has been living with a rare disease for almost five years. When 13-year-old Bella Damian-Ortiz was ...

A nonpathogenic monoclonal antibody might hold the key to successful treatment of neuromyelitis optica (NMO)—an autoimmune demyelinating disease characterized by lesions in the optic nerve and spinal ...